使用其内源标志物和消化系统疾病患者的遗传变异来表征血vonoprazan和CYP3A活性
Kenta Sakaguchi1, Takafumi Naito2, Kohei Hoshikawa1
1Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Drug metabolism and pharmacokinetics
|October 20, 2024
概括
在患有消化系统疾病的患者中,诺普拉桑的血水平有显著的变化. 由4β-基胆固醇 (4β-OHC) 表示的细胞染色体P450 3A (CYP3A) 活性部分解释了这些变异,这表明它在临床反应中发挥了作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 对诺普拉桑的临床反应显示出显著的个体间变异性.
- 了解影响vonoprazan药理动学的因素对于优化消化系统疾病的治疗至关重要.
研究的目的:
- 在患有消化系统疾病的患者中,描述血vonoprazan水平和细胞染色体P450 3A (CYP3A) 活性.
- 为了研究CYP3A活性的影响,通过其内源标记物4β-基胆固醇 (4β-OHC) 和基因变异对vonoprazan药理学的影响.
主要方法:
- 接受诺普拉赞治疗的53名患者被纳入.
- 测量了诺普拉桑及其代谢物 (ODA-VP) 的血度.
- 确定了血4β-OHC,CYP3A5和ABCB1基因型以及血胃素.
- 使用复合CYP3A蛋白评估了vonoprazan的CYP3A识别.
主要成果:
- 诺普拉桑的血水平显示出很大的个体间差异.
- 在血vonoprazan和4β-OHC水平之间发现了负相关性,这表明在更高的vonoprazan度下,CYP3A活性降低.
- 基因变异CYP3A5和ABCB1与诺普拉桑度没有显著的关联.
- 在治疗剂量下观察到诺普拉桑的和代谢.
- 通过4β-OHC评估的CYP3A活性部分解释了诺普拉桑血水平的变化.
结论:
- 在患有消化系统疾病的患者中,vonoprazan的血度差异很大.
- 而不是CYP3A5或ABCB1基因型,而是CYP3A活性,部分导致了这种变异性.
- 这些发现表明,CYP3A活性会影响诺普拉桑的药理动力学,并可能在确定临床反应方面发挥作用.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
32
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
90
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
90
Drug Distribution: Plasma Protein Binding
5.0K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.0K
Hepatic Drug Clearance: Effect of Protein Binding
161
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
161
Drug Concentrations: Measurements
336
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
336
Factors Affecting Drug Biotransformation: Biological
117
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
117


